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On behalf of the hepatology community in Slovakia,
we would like to convey our sincere congratulations to
the HBV Clinical Practice Guidelines panel and to the
leadership of EASL for publishing the ﬁrst EASL Clin-
ical Practice Guidelines [1]. We agree this important
move should be seen as a conceptually welcome and a
long-awaited step forward for EASL and for a particu-
lar ﬁeld of contemporary hepatology. It also represents
an important step for the prospective enhancement of
the science-driven basis and internationally recognised
competence of hepatology to provide the necessary
authority for shaping the future development and imple-
mentation of the discipline of hepatology in Europe [2].
The above statement stems from our decades-long
experience of establishing and developing hepatology
as a self-standing and fully-recognized specialty in our
country. At the end of quite a diﬃcult voyage, impor-
tant milestones have been passed and landmarks
reached. Among those one may mention the state’s oﬃ-
cial recognition of hepatology as a self-standing medical
specialty (Slovak Ministry of Health, 1998) [3], paral-
leled with its comprehensive integration into the health
care system and the system of postgraduate medical edu-
cation and training in Slovakia [4,5]. Among the strate-
gies that have proven to be helpful in fostering these
developments we can aﬃrm that the production of clin-
ical practice guidelines (CPG) played a crucial role.
Nowadays, the specialty of hepatology is fully recog-
nised also by the health care payers (state and private
health insurance companies) with an appropriate medi-
cine prescription mandate and acceptable reimburse-
ment policies. The existence and implementation of
CPG played an essential role in the winning of battles
considered complicated prior to this.
In these pioneering, sometimes even temporarily fail-
ing ‘developmental eﬀorts’, a signiﬁcant role was played
by the gradual establishment of the state-recognised sys-
tem of development, review, evaluation and updating of
CPG in Slovakia. The position of academia in these pro-
cesses has been essential and respectful. Evidence-based
guidelines, produced by oﬃcially appointed panels of
authors (the appointment is made by a fully transparent
process upon recommendation of the scientiﬁc medical
association, or associations of the relevant medical spe-cialty, or specialties), undergoes a step-wise review and
approval process, which involves also the health care
payers (health insurance companies) and regulators
(Ministry of Health). This process ensures a good guar-
antee that the CPG are actually implemented in the na-
tional health system and drug policies. As a result,
authoritative, evidence-based consensual documents
are produced that indeed have a decisive impact upon
the national prescription and reimbursement policies.
In the ﬁeld of hepatology, the Slovak Society of
Hepatology (SSH) has been, since the very beginning
of the process, the key initiator and professional-scien-
tiﬁc guarantee of CPG developed in a step-wise manner
for the most important diseases of the liver. The ﬁrst
‘national guidelines’ on treatment of chronic viral hepa-
titis were published in 1998 [6]. Since then, the 3rd gen-
eration of ‘on-demand’ updated guidelines on
diagnostics and therapy of viral hepatitis have been is-
sued. A new update is due later this year. The existence
of the latest EASL CPG on the management of chronic
hepatitis B – as the European evidence-based consensus
provide an excellent basis for the update and implemen-
tation of the planned renewed guidelines at our national
level.
The standard setting activity described above has also
created an excellent opportunity for the Slovak Associa-
tion to obtain undisputable authority and the chance to
inﬂuence the key health policies important for the man-
agement of liver diseases in Slovakia. It has also enabled
Slovak hepatologists to foster – ﬁrstly as an ‘awareness
building’, later on as a strong ‘advocacy’, and ﬁnally as
an established recognition of the ‘‘obvious” require-
ment: ‘‘the patients with serious diseases of the liver
should be cared for (ﬁrst of all) by hepatologists”, and
– albeit within the widest interdisciplinary collaboration:
‘‘the liver ‘belongs’ (in the ﬁrst place) to hepatology” [7].
We believe that the most noteworthy idea and mes-
sage of the publication of the actual EASL Clinical
Practice Guidelines is the provision of an evidence-based
international standard, exclusively guaranteed by acade-
mia, for clinical hepatology in Europe and beyond. In-
deed, the actual EASL Guidelines and the decision to
produce CPG for all important areas of hepatology,
including their regular updates, create a strong impetus
and provide a reliable basis for elaboration of CPG, and
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To the Editor:
Non-alcoholic fatty liver disease (NAFLD) is a dis-
ease on the increase in the Western world with vast clin-
ical implications. Patients with NAFLD are susceptible
to develop NASH and are at risk of complications when
undergoing a liver resection, particularly in living donor
liver transplantation procedures [1]. In this setting mod-
erate and severe steatosis are considered exclusion crite-
ria. Consequently, clinically representative animal
models yielding an adequate steatosis degree are imper-
ative to conduct mechanistic and interventional investi-
gations. Presently, most models are based on genetic or
dietary adaptations. With respect to the former, ob/ob
mice lacking the leptin gene and Zucker fa/fa rats lack-
ing the leptin receptor exhibit hyperphagia resulting in
obesity, insulin resistance, and steatosis. However, the
drawback of these models includes the dissimilar etiol-
ogy of steatosis induction vs. its clinical counterpart
(i.e., genes vs. diet). Moreover, experimental studies
show that liver regeneration in these models appears
to be impaired not due to steatosis per se, but due to
the leptin deﬁciency. A clinically representative model
for experimental steatosis would thus be of great value.
In 2004 Lieber et al. [2] introduced a model using a
liquid high-fat diet for the induction of NASH in Spra-
gue–Dawley rats, referred to as the Lieber–Decarli
(LDC) diet. Within 3 weeks the animals purportedly
developed panlobular steatosis with inﬂammatory foci,
in association with insulin resistance and increased he-
patic TNF-a levels and lipid peroxidation products,
i.e., clinical features of NASH. In a recent study pub-
lished in this Journal, Lieber et al. [3] used medium[7] Holoma´nˇ J. Hepatology – medical specialty. Lek Listy
1998;15:1–16 [Slovak].
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chain triglycerides to prevent LDC diet-induced NASH.
In this letter we would like to address several irreproduc-
ibility issues regarding the LDC diet and its solid high-
fat equivalent.
We have attempted to set up the LDC model in Wis-
tar rats following the authors’ exact methodology [2].
However, after a 3-week LDC diet none of the livers
(n = 5) showed any histological evidence of steatosis
(Fig. 1A). Our ﬁndings were recently corroborated by
Akin et al. [4] in Sprague–Dawley rats, where only
20% developed 1–2% microvesicular steatosis after a 3-
week LDC diet (Fig. 1B). In both studies, animals had
gained signiﬁcantly less weight (98 and 76 g, respec-
tively) after 3 weeks than the animals in the original
study (173 g). Alternatively, we attempted to induce ste-
atosis with a solid high-fat diet in accordance with Sve-
gliati-Baroni et al. [5]. A 3-, 5-, and 7-week diet resulted
in a mean ± SD histological steatosis degree of 10 ± 5%,
5 ± 3%, and 10 ± 9%, respectively, in Wistar rats (n = 5/
group) and 14 ± 11%, 2 ± 1%, and 0%, respectively, in
Sprague–Dawley rats (n = 5/group).
Next, the reproducibility of the LDC diet was evalu-
ated against other studies referring to the LDC diet.
Using the ISI Web of Science database (accessed 01/
15/2008), 53 articles citing the original work were re-
trieved: 38 experimental studies, 9 reviews, 5 clinical
studies, and 1 editorial paper. Of the 38 experimental
studies, 6 articles (Fig. 1C) reported the use of the
LDC diet, of which 2 actually followed its original
experimental 3-week diet protocol; both by Lieber
et al. [3,6]. In another study by Lieber et al. [7] the diet
was employed during 3 and 6 weeks. Interestingly, histo-
